// App-Quantinova.ai

2505 : A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors.

Researchers

Presenter

  • Antonio Jimeno

Principal Investigators

  • Michael S. Gordon

  • Jakob Dupont

  • Robert J. Stagg

  • Ann Kapoun

  • Lu Xu

  • Rainer Karl Brachmann

  • David C. Smith

  • Rashmi Chugh

  • Wells A. Messersmith

  • David S. Mendelson

Medical Centers

  • Pinnacle Oncology Hematology, Scottsdale, AZ

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MIOncoMed Pharmaceuticals, Inc., Redwood City, CAUniversity of Colorado Denver, Aurora, CO

  • Premiere Oncology of Arizona, Scottsdale, AZ

  • OncoMed Pharmaceuticals Inc., Redwood City, CA

  • University of Michigan, Ann Arbor, MI

  • University of Colorado Cancer Center, Aurora, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ipafricept

Outcome

  • Positive

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • I

Study Id's

  • NCT01608867

Sponsors

  • OncoMed Pharmaceuticals, Inc.

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved